Valuation: Prothena Corporation plc

Market Cap 450M 389M 363M 333M 627M 42.8B 637M 4.26B 1.67B 21.45B 1.69B 1.65B 70.92B P/E 2026 *
34.5x
P/E 2027 * -8.98x
Enterprise Value 450M 389M 363M 333M 627M 42.8B 637M 4.26B 1.67B 21.45B 1.69B 1.65B 70.92B EV / Sales 2026 *
5.37x
EV / Sales 2027 * 17x
Free-Float
81.43%
Yield 2026 *
-
Yield 2027 * -
1 day+2.10%
1 week+7.88%
Current month+7.88%
1 month-11.07%
3 months-18.36%
6 months-1.68%
Current year-8.27%
1 week 8.04
Extreme 8.04
8.85
1 month 8
Extreme 8
9.82
Current year 7.73
Extreme 7.73
11.8
1 year 7.39
Extreme 7.3852
11.8
3 years 4.32
Extreme 4.32
63.64
5 years 4.32
Extreme 4.32
79.75
10 years 4.32
Extreme 4.32
79.75
Manager TitleAgeSince
Chief Executive Officer 57 30/09/2016
Director of Finance/CFO 52 01/04/2013
Chief Operating Officer 52 29/09/2021
Director TitleAgeSince
Chairman 76 20/12/2012
Director/Board Member 72 20/12/2012
Director/Board Member 63 20/12/2012
Date Insider Type Main position Quantity % Market Cap.
29/07/26 Sell

General Counsel

-8,386 0.0160%
29/07/26 Sell

Executive/Senior Manager

-7,662 0.0146%
28/07/26 Fiscal year

Controller/Auditor

45,000 0.0860%
Change 5-day change 1-year change 3-year change Capi.($)
+2.10%+7.88%+13.91%-85.63% 450M
+8.49%+20.55%+70.77%+110.32% 68.12B
+1.25%+2.44%+34.27%+70.43% 55.18B
-1.09%+32.96%+19.67%+494.56% 28.63B
+10.83%+18.38%+56.20%+6.03% 23.99B
+2.72%+3.41%-16.11%-7.96% 23.53B
+6.50%+7.56%+44.65%-21.73% 18.45B
+6.20%+11.51%+33.87%+693.38% 16.44B
-3.88%+16.98%+199.30%+359.77% 15.83B
+3.58%+1.96%+43.35%+163.76% 13.4B
Average +3.67%+11.30%+49.99%+178.29% 26.4B
Weighted average by Cap. +4.35%+13.09%+50.63%+168.04%

Financials

2026 *2027 *
Net sales 83.82M 72.51M 67.71M 62.11M 117M 7.98B 119M 794M 312M 4B 315M 308M 13.22B 26.4M 22.84M 21.33M 19.56M 36.8M 2.51B 37.38M 250M 98.2M 1.26B 99.14M 96.97M 4.16B
Net income 14.29M 12.36M 11.55M 10.59M 19.92M 1.36B 20.24M 135M 53.17M 682M 53.68M 52.5M 2.25B -52.4M -45.33M -42.33M -38.83M -73.04M -4.99B -74.2M -497M -195M -2.5B -197M -192M -8.26B
Net Debt - -
Logo Prothena Corporation plc
Prothena Corporation plc is an Ireland-based late-stage clinical biotechnology company. The Company is engaged in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid diseases. The Company is advancing a pipeline of therapeutic candidates for a range of indications and targets to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins. The Company’s pipeline includes both wholly owned and partnered programs being developed for the potential treatment of diseases, including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and a range of other neurodegenerative diseases. Its clinical programs include birtamimab for the potential treatment of AL amyloidosis, prasinezumab for the potential treatment of Parkinson’s disease, NNC6019/PRX004 for the potential treatment of ATTR amyloidosis, and PRX005 and PRX012 for the potential treatment of Alzheimer’s disease.
Employees
67
Date Price Change Volume
07/08/26 $8.760 +2.10% 481,884
06/08/26 $8.580 +1.06% 418,686
05/08/26 $8.490 0.00% 489,491
04/08/26 $8.490 +1.92% 329,913
03/08/26 $8.330 +2.59% 566,000
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
8.760USD
Average target price
21.40USD
Spread / Average Target
+144.29%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PRTA Stock